Related Experiment Video

Updated: Aug 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Advances in immunomodulating therapy of HBV infection

Chee-Kin Hui1, George Kk Lau

  • 11. MRC Cancer Cell Unit, University of Cambridge, Cambridge, UK.

International Journal of Medical Sciences
|June 22, 2005
PubMed

Insights

Current treatments for chronic hepatitis B virus (HBV) infection have limited efficacy and can lead to drug resistance. Immunotherapies offer a promising alternative to restore HBV-specific T cell responses.

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Chronic hepatitis B virus (HBV) infection poses significant risks for liver cirrhosis and hepatocellular carcinoma.
  • Current antiviral therapies like interferon-alpha, lamivudine, and adefovir dipivoxil have limited efficacy (20-30%) and risk drug resistance.
  • Limitations in current treatments necessitate exploring alternative therapeutic strategies.

Purpose of the Study:

  • To explore immunotherapeutic strategies as an alternative approach for chronic HBV infection.
  • To investigate methods for restoring effective virus-specific T cell responses in patients with chronic HBV.

Main Methods:

  • Review of existing literature on current antiviral therapies for chronic HBV.
  • Exploration of immunotherapeutic approaches, including adoptive transfer of HBV immunity, pegylated interferon, and therapeutic vaccines.
  • Focus on restoring virus-specific T cell responses.

Main Results:

  • Current antiviral treatments demonstrate suboptimal efficacy and potential for resistance development.
  • Immunotherapeutic strategies present a viable alternative for managing chronic HBV infection.
  • Restoring T cell responses is a key target for novel therapies.

Conclusions:

  • There is a critical need for alternative therapies beyond current antivirals for chronic HBV.
  • Immunotherapy, by restoring T cell immunity, offers a promising avenue for HBV treatment.
  • Future research should focus on developing and evaluating these immunotherapeutic approaches.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...